Skip to content
value.today
Verastem, Inc. logo

Verastem, Inc.

VSTM
$1.1 Bmarket cap on Oct 19, 2026+409.4% since Jan 2024
1D
+16.1%
Compare
World rank
#8,924
Revenue
$31 M
For year ending December-2025
Net income
$-209 M
-677.7% margin
SEC filing
Employees
48
As on 2021
value.today research

Verastem, Inc. in brief

Verastem, Inc. is a listed company in the Biotechnology industry, based in Needham, Massachusetts, USA. It was founded in 2010. Its market value was $1.1 B on 19 October 2026, which makes it the 8,924th largest listed company in the world and the 2,003rd largest in the USA on this site. In the year to December 2025 it had sales of $31 M and a net loss of $209 M. It employs about 48 people and Dan Paterson is its chief executive. Its shares trade under the symbol VSTM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Verastem, Inc.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Verastem, Inc. timeline

5 events, 2010–2020
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2011
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2012
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2018
  8. •
    Legal Entity Identifier issued
    LEI 549300IY0EFBIU8NQC81 registered.
  9. 2020
  10. 💰
    Record revenue of $89 million
    FY2020, the highest of the 7 years on record.

Events of Verastem, Inc. from Wikidata, SEC EDGAR, the company record, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$294 M$589 M$883 M$1.2 B2020202120222023202420252026

World rank over time

▲ up 9,847 places since 2020
2020-01-01: #18793#18,79320202021-01-01: #12766#12,76620212022-01-07: #15856#15,85620222022-12-25: #23341#23,34120222023-07-30: #16649#16,64920232024-01-05: #17533#17,53320242026-03-08: #7487#7,48720262026-08-01: #11558#11,55820262026-10-14: #9694#9,69420262026-10-19: #8946#8,9462026

Rank in USA: #3,686 (Jan 2020) · #2,795 (Jan 2021) · #3,314 (Jan 2022) · #4,530 (Dec 2022) · #3,383 (Jul 2023) · #3,197 (Jan 2024) · #1,323 (Mar 2026) · #2,428 (Aug 2026) · #2,095 (Oct 2026) · #2,004 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
35.3×
Price / book
19.1×
Free cash flow yield
-9.6%
Net margin
-677.7%
Operating margin
-550.4%
Return on equity
-366.2%
Liabilities / assets
76.8%
Net debt
$-48M
Revenue growth
+209.1%
R&D / revenue
370.8%
Revenue per employee
$644 K
Profit per employee
$-4.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $27M, net income $-72M$27MFY18Fiscal year ending Dec 2019: revenue $17M, net income $-149M$17MFY19Fiscal year ending Dec 2020: revenue $89M, net income $-68M$89MFY20Fiscal year ending Dec 2021: revenue $2M, net income $-71M$2MFY21Fiscal year ending Dec 2022: revenue $3M, net income $-74M$3MFY22Fiscal year ending Dec 2023: revenue —, net income $-87M—FY23Fiscal year ending Dec 2024: revenue $10M, net income $-131M$10MFY24Fiscal year ending Dec 2025: revenue $31M, net income $-209M$31MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$31M+209.1%$-170M$-209M-677.7%
Dec 2024$10M—$-115M$-131M-1306.4%
Dec 2023——$-92M$-87M—
Dec 2022$3M+26.8%$-73M$-74M-2838.8%
Dec 2021$2M-97.7%$-61M$-71M-3473.2%
Dec 2020$89M+407.0%$-49M$-68M-76.5%
Dec 2019$17M-34.7%$-132M$-149M-854.6%
Dec 2018$27M—$-95M$-72M-271.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-138M——$-3.02—
Dec 2024$-105M$0M$-105M$-3.66—
Dec 2023$-86M——$-3.96—
Dec 2022$-64M——$-4.57—
Dec 2021$-54M$0M$-54M$-4.90—
Dec 2020$-34M$0M$-34M$-0.44—
Dec 2019$-139M$0M$-139M$-2.00—
Dec 2018$-75M$2M$-76M$-1.37—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-65M—Dec ’24Three months to Mar 2025: revenue —, net income $-52M—Mar ’25Three months to Jun 2025: revenue $2M, net income $-26M$2MJun ’25Three months to Sep 2025: revenue $11M, net income $-99M$11MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-33M—Dec ’25Three months to Mar 2026: revenue $19M, net income $-37M$19MMar ’26Three months to Jun 2026: revenue $40M, net income $-35M$40MJun ’26Three months to Sep 2026: revenue $24M, net income $-75M$24MSep ’26

Latest quarter to Sep 2026: revenue $24M (+113.6% on a year earlier), net income $-75M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Verastem, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$31 M
Operating income
$-170 M
Net income
$-209 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$246 M
Total liabilities
$189 M
Total equity
$57 M

As of December-2025

Top 100 institutional investors in Verastem, Inc.#

As of Sep 30, 2026
162 institutions held 88.4 M shares (about 70.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 39.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Verastem, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.9,515,785+323,338 (+3.52%)7.55%$77 MNov 13, 2026
2RTW Investments, LP6,718,081+82,288 (+1.24%)5.33%$54 MNov 16, 2026
3Deep Track Capital, LP5,740,8500 (0.00%)4.56%$46 MNov 16, 2026
4Armistice Capital, LLC5,724,000-1,300,000 (-18.51%)4.54%$46 MNov 16, 2026
5Rosalind Advisors, Inc.4,236,509+250,000 (+6.27%)3.36%$34 MNov 16, 2026
6State Street Corp4,020,999-1,112,860 (-21.68%)3.19%$32 MNov 12, 2026
7MPM Bioimpact LLC3,851,604New3.06%$31 MNov 16, 2026
8Vanguard Capital Management LLC3,818,793-32,715 (-0.85%)3.03%$31 MNov 13, 2026
9Foresite Capital Management VI LLC3,146,6310 (0.00%)2.50%$25 MNov 16, 2026
10Stonepine Capital Management, LLC3,042,775-306,852 (-9.16%)2.41%$24 MNov 13, 2026
11Opaleye Management Inc.2,753,333+953,333 (+52.96%)2.18%$22 MNov 16, 2026
12Vanguard Portfolio Management LLC2,555,924-710,946 (-21.76%)2.03%$21 MNov 13, 2026
13Balyasny Asset Management L.P.2,299,020+612,445 (+36.31%)1.82%$19 MNov 16, 2026
14Geode Capital Management, LLC2,184,016+109,871 (+5.30%)1.73%$18 MNov 6, 2026
15Morgan Stanley1,917,771+1,201,949 (+167.91%)1.52%$15 MNov 13, 2026
16Nantahala Capital Management, LLC1,779,840-5,389,800 (-75.18%)1.41%$14 MNov 13, 2026
17Acorn Capital Advisors, LLC1,469,1530 (0.00%)1.17%$12 MNov 16, 2026
18Goldman Sachs Group Inc1,443,118-1,278,060 (-46.97%)1.15%$12 MNov 16, 2026
19Alyeska Investment Group, L.P.1,225,360-1,064,265 (-46.48%)0.97%$10 MNov 16, 2026
20AIGH Capital Management LLC1,121,682-805,318 (-41.79%)0.89%$9 MNov 2, 2026
21Franklin Templeton Inc1,105,850+829 (+0.08%)0.88%$9 MNov 12, 2026
22NEXTBio Capital Management LP906,742-400,058 (-30.61%)0.72%$7 MNov 13, 2026
23Point72 Asset Management, L.P.901,995New0.72%$7 MNov 16, 2026
24Bank Of America Corp /de/849,889-40,086 (-4.50%)0.67%$7 MNov 16, 2026
25FMR LLC842,128+215,830 (+34.46%)0.67%$7 MNov 10, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Verastem, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26AQR Capital Management LLC798,754-135,811 (-14.53%)0.63%$6 MNov 16, 2026
27Panagora Asset Management Inc715,865+48,991 (+7.35%)0.57%$6 MNov 12, 2026
28Hennion & Walsh Asset Management, Inc.699,828+130,633 (+22.95%)0.56%$6 MOct 13, 2026
29Pinnacle Financial Partners, Inc.695,880-390,560 (-35.95%)0.55%$6 MNov 13, 2026
30Northern Trust Corp671,489+19,994 (+3.07%)0.53%$5 MNov 16, 2026
31Barclays PLC671,045+577,637 (+618.40%)0.53%$5 MNov 6, 2026
32Citigroup Inc628,458+508,223 (+422.69%)0.50%$5 MNov 4, 2026
33Vanguard Fiduciary Trust Co609,042-7,820 (-1.27%)0.48%$5 MNov 13, 2026
34Jane Street Group, LLC467,585New0.37%$4 MNov 12, 2026
35Torray Investment Partners LLC464,381-13,074 (-2.74%)0.37%$4 MOct 30, 2026
36Trexquant Investment LP454,265New0.36%$4 MNov 16, 2026
37Exome Asset Management LLC429,0410 (0.00%)0.34%$3 MNov 16, 2026
38UBS Group AG427,736-176,744 (-29.24%)0.34%$3 MNov 10, 2026
39Jefferies Financial Group Inc.414,241-82,288 (-16.57%)0.33%$3 MNov 5, 2026
40Virtus Investment Advisers, LLC411,097+127,467 (+44.94%)0.33%$3 MNov 12, 2026
41Ameriprise Financial Inc384,936New0.31%$3 MNov 16, 2026
42Raymond James Financial Inc339,834+140,997 (+70.91%)0.27%$3 MNov 12, 2026
43Palo Alto Investors LP325,480+15,795 (+5.10%)0.26%$3 MNov 16, 2026
44Woodline Partners LP313,911New0.25%$3 MNov 16, 2026
45Susquehanna International Group, LLP311,851+73,422 (+30.79%)0.25%$3 MNov 16, 2026
46Millennium Management LLC295,622-1,782,381 (-85.77%)0.23%$2 MNov 16, 2026
47Wellington Management Group LLP268,490+216,790 (+419.32%)0.21%$2 MNov 16, 2026
48Nuveen, LLC260,452+1,519 (+0.59%)0.21%$2 MNov 10, 2026
49Charles Schwab Investment Management Inc251,846+7,896 (+3.24%)0.20%$2 MNov 16, 2026
50Ikarian Capital, LLC213,8650 (0.00%)0.17%$2 MNov 16, 2026
51Bank of New York Mellon Corp203,807+18,863 (+10.20%)0.16%$2 MNov 5, 2026
52BNP Paribas Financial Markets193,418+181,985 (+1591.75%)0.15%$2 MNov 12, 2026
53Toronto Dominion Bank184,229-276,184 (-59.99%)0.15%$1 MNov 16, 2026
54Jump Financial, LLC176,874-130,626 (-42.48%)0.14%$1 MNov 13, 2026
55Janney Montgomery Scott LLC152,647+208 (+0.14%)0.12%$1 MNov 12, 2026
56Weiss Asset Management LP143,819New0.11%$1 MNov 16, 2026
57Quantinno Capital Management LP137,023+90,686 (+195.71%)0.11%$1 MNov 13, 2026
58Creative Planning120,745+73,157 (+153.73%)0.10%$1 MNov 2, 2026
59Invesco Ltd.120,272-4,805 (-3.84%)0.10%$1 MNov 12, 2026
60Royal Bank Of Canada103,174-5,689 (-5.23%)0.08%$1 MNov 16, 2026
61Rafferty Asset Management, LLC97,537+3,333 (+3.54%)0.08%$1 MNov 13, 2026
62Rhumbline Advisers90,349+6,671 (+7.97%)0.07%$1 MNov 10, 2026
63Alliancebernstein L.P.83,050-34,040 (-29.07%)0.07%$1 MNov 16, 2026
64Deutsche Bank AG\77,867-9,801 (-11.18%)0.06%$1 MNov 6, 2026
65ADAR1 Capital Management, LLC72,800-3,000 (-3.96%)0.06%$1 MNov 16, 2026
66Entropy Technologies, LP70,240New0.06%$1 MNov 13, 2026
67Boothbay Fund Management, LLC68,5410 (0.00%)0.05%$1 MNov 16, 2026
68Price T Rowe Associates Inc /MD/65,5650 (0.00%)0.05%$1 MNov 16, 2026
69Engineers Gate Manager LP60,053New0.05%$0 MNov 16, 2026
70Mercer Global Advisors Inc /adv59,732+16,929 (+39.55%)0.05%$0 MNov 16, 2026
71SEI Investments Co58,034+31,412 (+117.99%)0.05%$0 MNov 10, 2026
72Russell Investments Group, Ltd.56,851+27,273 (+92.21%)0.05%$0 MNov 6, 2026
73Aquatic Capital Management LLC56,481New0.04%$0 MNov 16, 2026
74Public Employees Retirement System Of Ohio51,218New0.04%$0 MNov 16, 2026
75Jpmorgan Chase & Co49,888+14,501 (+40.98%)0.04%$0 MNov 12, 2026
76MetLife Investment Management, LLC47,399-11,850 (-20.00%)0.04%$0 MNov 16, 2026
77MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.46,692-876 (-1.84%)0.04%$0 MNov 16, 2026
78WINTON GROUP Ltd46,600+22,400 (+92.56%)0.04%$0 MNov 12, 2026
79Cetera Investment Advisers42,885-527 (-1.21%)0.03%$0 MNov 13, 2026
80Envestnet Asset Management Inc42,837-1,744 (-3.91%)0.03%$0 MNov 16, 2026
81Stifel Financial Corp38,047-306 (-0.80%)0.03%$0 MNov 12, 2026
82Renaissance Technologies LLC34,940New0.03%$0 MNov 12, 2026
83Profund Advisors LLC34,687-12,797 (-26.95%)0.03%$0 MOct 29, 2026
84Wells Fargo & Company/mn34,052-46,635 (-57.80%)0.03%$0 MNov 16, 2026
85Aries Wealth Management32,833+2,000 (+6.49%)0.03%$0 MOct 23, 2026
86Diversified Trust Co32,2450 (0.00%)0.03%$0 MNov 6, 2026
87Nomura Holdings Inc31,488New0.03%$0 MNov 16, 2026
88XTX Topco Ltd31,057-530,734 (-94.47%)0.02%$0 MNov 16, 2026
89Vanguard Global Advisers, LLC30,905+385 (+1.26%)0.02%$0 MNov 13, 2026
90Gotham Asset Management, LLC30,600New0.02%$0 MNov 16, 2026
91Quadrature Capital Ltd30,599-16,383 (-34.87%)0.02%$0 MNov 13, 2026
92iA Global Asset Management Inc.30,108New0.02%$0 MOct 29, 2026
93Squarepoint Ops LLC29,739New0.02%$0 MNov 9, 2026
94New York State Common Retirement Fund27,700+22,500 (+432.69%)0.02%$0 MNov 17, 2026
95Fox Run Management, L.L.C.25,641New0.02%$0 MNov 12, 2026
96Police & Firemen's Retirement System of New Jersey23,122+3,737 (+19.28%)0.02%$0 MNov 9, 2026
97Tower Research Capital LLC (TRC)22,664+15,105 (+199.83%)0.02%$0 MNov 16, 2026
98Manufacturers Life Insurance Company, The21,932-322 (-1.45%)0.02%$0 MNov 13, 2026
99Vanguard Personalized Indexing Management, LLC21,903+9,949 (+83.23%)0.02%$0 MNov 16, 2026
100Wealth Enhancement Advisory Services, LLC19,745+246 (+1.26%)0.02%$0 MOct 13, 2026

All 162 institutional investors, with who bought and sold →

Mutual funds holding Verastem, Inc.#

110 funds hold shares worth $85 M (about 15.7% of the company). Since their previous reports 85 added shares and 20 sold, buying $29 M net.
Mutual funds holding Verastem, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.3.39 M$13 M2.7%0.12%+68%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.81 M$11 M2.2%<0.01%+16%Jun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.1.40 M$8 M1.1%0.04%+357%Jul 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.07 M$8 M1.6%<0.01%+28%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC872,784$5 M0.69%0.01%+32%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.960,598$4 M0.76%<0.01%+17%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC701,337$3 M0.56%0.06%+239%May 29, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors750,135$3 M0.60%0.02%+146%Jun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.401,744$2 M0.32%0.20%no changeJul 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC575,899$2 M0.46%0.04%+37%Jun 30, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.536,651$2 M0.43%0.07%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC378,589$2 M0.30%<0.01%+15%May 31, 2026
🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC260,400$2 M0.21%0.06%newJul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.343,561$1 M0.27%<0.01%+30%May 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.330,409$1 M0.26%0.07%+382%Jun 30, 2026
🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc.295,455$1 M0.23%0.19%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.194,439$1 M0.15%0.01%+32%Jul 31, 2026
🇺🇸 iShares Genomics Immunology and Healthcare ETFBlackRock Fund Advisors178,719$1 M0.14%0.54%+54%Jul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors268,301$1 M0.21%0.07%+59%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC125,896$1 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC115,157$1 M0.09%0.14%−2.0%Jul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors173,404$1 M0.14%<0.01%+88%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds170,345$1 M0.14%0.08%+99%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC106,415$1 M0.08%0.02%+33%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC133,691$1 M0.11%<0.01%+18%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC149,314$1 M0.12%<0.01%+37%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.128,379$1 M0.10%<0.01%−0.8%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP83,454$0 M0.07%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC109,968$0 M0.09%<0.01%+22%May 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC81,901$0 M0.06%0.02%+5.3%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP78,050$0 M0.06%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP58,252$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC86,908$0 M0.07%<0.01%+27%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC75,130$0 M0.06%0.02%+50%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC74,795$0 M0.06%0.02%+162%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.49,159$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC64,022$0 M0.05%<0.01%newMay 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC45,927$0 M0.04%<0.01%+12%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC53,429$0 M0.04%<0.01%+49%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation58,800$0 M0.05%<0.01%+67%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC37,988$0 M0.03%0.01%+31%Jul 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC55,509$0 M0.04%0.02%newJun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC36,349$0 M0.03%0.11%—Apr 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC30,578$0 M0.02%<0.01%+22%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC42,609$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC41,960$0 M0.03%<0.01%+146%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.41,768$0 M0.03%<0.01%+26%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.41,412$0 M0.03%<0.01%+25%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.35,015$0 M0.03%<0.01%+27%May 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors38,739$0 M0.03%<0.01%+97%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.37,586$0 M0.03%<0.01%−14%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC34,308$0 M0.03%0.01%+94%Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.29,304$0 M0.02%0.01%−35%May 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company27,713$0 M0.02%<0.01%+40%May 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors30,754$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC20,152$0 M0.02%0.01%newJul 31, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC29,828$0 M0.02%0.08%+270%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.18,933$0 M0.02%0.03%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.25,900$0 M0.02%<0.01%+14%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.22,643$0 M0.02%<0.01%+32%May 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC22,930$0 M0.02%<0.01%+38%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC12,762$0 M0.01%0.02%+14%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC12,757$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC17,836$0 M0.01%0.03%+49%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC17,727$0 M0.01%<0.01%+29%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS17,450$0 M0.01%<0.01%+33%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC16,774$0 M0.01%<0.01%+37%Jun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.15,983$0 M0.01%0.03%newJun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC10,704$0 M<0.01%0.03%—Mar 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.9,462$0 M<0.01%<0.01%+9.8%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC14,323$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC9,354$0 M<0.01%0.02%+51%Jul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION11,200$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC12,696$0 M0.01%0.03%+310%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.12,530$0 M<0.01%<0.01%+34%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC12,084$0 M<0.01%<0.01%+123%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.12,044$0 M<0.01%<0.01%+77%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC11,690$0 M<0.01%0.01%+34%Jun 30, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS11,598$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS7,538$0 M<0.01%0.02%+35%Jul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC6,891$0 M<0.01%<0.01%+172%Jul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC10,378$0 M<0.01%<0.01%+42%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.9,234$0 M<0.01%<0.01%+67%Jun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP5,730$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC5,492$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC7,275$0 M<0.01%0.02%+164%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC7,056$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.5,907$0 M<0.01%<0.01%+64%May 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP4,267$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,378$0 M<0.01%<0.01%+70%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC5,705$0 M<0.01%0.01%+35%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management5,483$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC5,239$0 M<0.01%<0.01%+30%Jun 30, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION4,000$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,833$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION3,750$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,997$0 M<0.01%<0.01%−11%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC3,154$0 M<0.01%<0.01%+36%May 31, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust3,560$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,192$0 M<0.01%<0.01%+68%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Verastem, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$1.1 M
32 sales, 6 insiders
Net, 12 months
-$1.1 M
open market only
Insiders on file
40
since
-$574 K$0Dec 2023: bought $0 (0 trades), sold $13 K (8 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $101 K (2 trades)Feb 2024: bought $0 (0 trades), sold $126 K (1 trades)Mar 2024: bought $0 (0 trades), sold $18 K (8 trades)Apr 2024: bought $0 (0 trades), sold $65 (1 trades)AprJun 2024: bought $0 (0 trades), sold $6 K (8 trades)Jul 2024: bought $0 (0 trades), sold $18 (1 trades)Aug 2024: bought $0 (0 trades), sold $7 K (1 trades)Sep 2024: bought $0 (0 trades), sold $5 K (8 trades)SepOct 2024: bought $0 (0 trades), sold $17 (1 trades)Nov 2024: bought $0 (0 trades), sold $3 K (1 trades)Dec 2024: bought $0 (0 trades), sold $8 K (8 trades)Jan 2025: bought $0 (0 trades), sold $45 K (2 trades)Jan 25Feb 2025: bought $0 (0 trades), sold $5 K (1 trades)Mar 2025: bought $0 (0 trades), sold $8 K (5 trades)May 2025: bought $0 (0 trades), sold $574 K (3 trades)Jun 2025: bought $0 (0 trades), sold $119 K (6 trades)JunAug 2025: bought $0 (0 trades), sold $8 K (1 trades)Sep 2025: bought $0 (0 trades), sold $13 K (5 trades)Oct 2025: bought $0 (0 trades), sold $75 K (1 trades)Nov 2025: bought $0 (0 trades), sold $282 K (9 trades)NovDec 2025: bought $0 (0 trades), sold $196 K (13 trades)Jan 2026: bought $0 (0 trades), sold $110 K (2 trades)Feb 2026: bought $0 (0 trades), sold $6 K (1 trades)May 2026: bought $0 (0 trades), sold $5 K (1 trades)MayJun 2026: bought $0 (0 trades), sold $104 K (3 trades)Aug 2026: bought $0 (0 trades), sold $8 K (1 trades)Sep 2026: bought $0 (0 trades), sold $424 (1 trades)Oct 2026: bought $0 (0 trades), sold $373 K (2 trades)OctNov 2026: bought $0 (0 trades), sold $12 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Verastem, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Dan PatersonPresident and CEO, DirectorSell10b5-1 plan-1,299$9.600$12 K651,413Form 4
filed Dan PatersonPresident and CEO, DirectorSell10b5-1 plan-44,121$8.000$353 K652,712Form 4
filed Daniel CalkinsChief Financial OfficerSell10b5-1 plan-2,566$8.000$21 K123,781Form 4
filed Dan PatersonPresident and CEO, DirectorGrant or award10b5-1 plan-106,893——696,833Form 4
filed Daniel CalkinsChief Financial OfficerGrant or award10b5-1 plan-8,333——126,347Form 4
filed Daniel CalkinsChief Financial OfficerSell10b5-1 plan-55$7.700$424118,014Form 4
filed Dan PatersonPresident and CEO, DirectorSell10b5-1 plan-1,302$5.810$8 K589,940Form 4
filed Daniel CalkinsChief Financial OfficerSell10b5-1 plan-4,032$4.180$17 K117,295Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Verastem, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
19.7 M
25.3% of shares · 5.17 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-10-14 13:42 UTC, code LUDP, resumed 13:47 UTC
  • 2025-05-08 15:10 UTC, code T3, resumed 17:45 UTC

Fails to deliver

  • : 20,741 shares at $8.65
  • : 31,567 shares at $7.71
  • : 107,998 shares at $7.45
  • : 148,209 shares at $8.11
  • : 216,889 shares at $8.27

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Verastem, Inc. scorecard#

Passes 3 of the 17 checks that could be worked out: strongest in growth (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 19, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median19.1×Price to book 19.1× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median35.3×Price to sales 35.3× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-9.6%Free cash flow is -9.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 3
    • ✓Revenue grew in the newest year209.1%Revenue up 209.1% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.02 vs -3.66Diluted EPS -3.02 in fiscal 2025 against -3.66 the year before (report's currency).
    • ✗Net income higher than five years earlier-$209 M-$209 M in fiscal 2025 against -$68 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$209 MNet income -$209 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-550.4%-550.4% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-550.4%-550.4% in fiscal 2025 against -2805.4% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities3.1×Current ratio 3.09 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-149.2×Operating income -149.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-4.58Z-score -4.58 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year94.1%Diluted shares up 94.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Verastem, Inc.'s statements, beside the median of Biotechnology.

Verastem, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-550.4%-60.5%
Net margin-677.7%-68.9%
Revenue growth209.1%15.8%

4of 7on the Piotroski tests of financial strength

  • Net loss of $209 million, the 15th loss-making year in a row.
  • The share count rose 94.1% in the year.
  • Operating income covers the interest bill only -149.2 times.

Verastem, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Verastem, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue3110—2.62.1891727——
Cost of revenue———————0.2——
Research and development115816151394146444620
Selling, general and administrative814431252463101772117
General and administrative————————2117
Operating expenses———————1226837
Total costs and expenses20112592766313815012268—
Operating income−170−115−92−73−61−49−132−95−68−37
Interest and finance income4.14.16.21.20.20.54.42.60.60.6
Interest expense and finance costs1.14.64.12.110.016215.80.6—
Other non-operating income (expense)−0.2−0.1−0.10.0—−1.3−0.626——
Income before tax−209−130−87−74−71−68−149−72——
Income tax—0.2—000.200——
Net income including minority interests−209−131−87−74−71−68−149−72−68−36
Net income attributable to shareholders−209−131−87−74−71−68−149−72−68−36
Earnings per share, basic-3.02-3.66-3.96-4.57r-4.90r-0.44-2.00-1.12-1.76-0.99
Earnings per share, diluted-3.02-3.66-3.96r-4.57r-4.90r-0.44-2.00-1.37-1.76-0.99
Shares, weighted average (basic)69362216r15r15375653837
Shares, weighted average (diluted)69362216r15r0.2r75693837
Balance sheet
Cash and cash equivalents2058978752168441308232
Short-term investments——59137973321204.5—
Inventory1.8—————3.10.3——
Other current assets7.65.96.64.95.03.53.8r3.01.10.4
Current assets2239514493106145852538881
Property, plant and equipment—0.00.00.10.20.40.91.40.91.4
Right-of-use (leased) assets0.51.41.21.82.32.73.1———
Other intangible assets16—————2022——
Long-term investments—————6.0————
Total assets246102150951091541452779084
Accounts payable124.07.24.92.31.99.7109.24.1
Current liabilities72312622191730371711
Long-term debt————————15—
Lease liabilities (non-current)—0.50.51.52.32.93.5———
Total liabilities189130714821391381533211
Retained earnings−1,165−956−825−738−664−593−525−376−303−235
Shareholders' equity57−295747881157.21245872
Total liabilities and equity246102150951091541452779084
Shares outstanding78452517r18517080745137
Cash-flow statement
Depreciation and amortization—————————0.7
Share-based compensation9.47.35.96.07.78.18.56.75.06.3
Cash from operating activities−138−105−86−64−54−34−139−75−57−29
Capital expenditure—−0.0——−0.2−0.0−0.0−1.5—−0.0
Intangible assets bought−9.6——————−22——
Cash from investing activities−9.660−44660.1−4790−1384437r
Debt issued————————15—
Debt repaid−43—−0.3——−37−12———
Shares issued1971491276.7106—10548—
Cash from financing activities26355134526.970−2.426163−0.0
Change in cash11610.03.354−47−11−5148507.4r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Verastem, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product revenue, net(total)$31 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Verastem, Inc. operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Verastem, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Verastem, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Verastem, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.3 M
Dan Paterson
Other top executives, average
$958 K
the CEO earned 2.5× this
$100 invested is now
$160
Verastem, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dan Paterson$2.3 M$3.8 M$958 K$160
2024Dan Paterson$2.5 M$2.4 M$741 K$107
2023Dan Paterson$3.6 M$3.2 M$623 K$169

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Verastem, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 3 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 5

Verastem, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officersResults announced8-K
Material agreementNew debt8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Material agreementAgreement endedNew debtUnregistered share saleResults announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 14, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Verastem, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2020$100 MPrivate placement after listing$50 to $250 million21equitySEC
Feb 2014$4 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Jul 2012$2 MNo. 3$2 to $10 million1equitySEC
Nov 2011$20 MNo. 2$10 to $50 million36equitySEC
Jul 2011$32 MNo. 1$10 to $50 million23equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Verastem, Inc.#

3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $165 K a year.

Certified, FY2026
3
#1,359 among companies on value.today
Worker positions
3
Median wage offered
$165 K
a year, full-time
Applications filed
3
Verastem, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Assoc. Dir. Drug Substance Development & Manufacturing, CMCIndustrial Production Managers1$190 K
Senior Manager, Pharmacovigilance Operations SpecialistMedical Scientists, Except Epidemiologists1$156 K
Senior Manager, Statistical ProgrammingComputer Programmers1$165 K

Where: Frisco, TX 1 · Canton, MI 1 · Shoreview, MN 1

Verastem, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202633$165 K3
FY202411$155 K1
FY202311$134 K1
FY202222$159 K2
FY202111$145 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Verastem Inc.

FDA drug approvals: Verastem, Inc.#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2025.

Approvals held
1
New molecular entities
1
New uses approved
0
efficacy supplements
Generics
0
1 new drugs, 0 biologics
Verastem, Inc.: latest FDA approvals
ApprovedDrugKind
2025-05-08Avmapki Fakzynja Co-Pack (Copackaged)new moleculeAvutometinib Potassium, Defactinib Hydrochloride · NDA219616New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (VERASTEM INC), so they follow acquisitions

Layoffs at Verastem, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
71
2015–2020
Latest
31 people
2020-02-27
Verastem, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020·31··········31
2019·········40··40
2015············—
Verastem, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
31 peopleRestructuring planSEC 8-K“Item 2.05 Costs Associated with Exit or Disposal Activities On February 27, 2020, the Company committed to an operational plan to reduce overall operating expenses, including the e…”Filing
40 peopleRestructuring planSEC 8-K“Item 2.05 Costs Associated with Exit or Disposal Activities On October 28, 2019, the Company committed to an operational plan to reduce overall operating expenses, including the el…”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

Discuss Verastem, Inc.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of Verastem, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $373,496 in 2 trades. Awards, option exercises and shares withheld for tax are not counted.

  • Results announced on 14 October 2026automatic update · Oct 14, 2026

    Verastem, Inc. announced results on 14 October 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $24 million (up 114% from a year earlier) and a net loss of $75 million.

  • Mutual funds: 110 funds hold $85 millionautomatic update · Jul 31, 2026

    110 mutual funds in 1 country hold shares of Verastem, Inc. worth $85 million, about 15.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 85 funds added shares and 20 sold; on balance they bought $29 million. Share splits are not counted as trading.

How Verastem, Inc. compares in Biotechnology

  • Market cap$1.1 B · higher than 69% of 726
  • Revenue$31 M · higher than 54% of 647
  • Net margin-677.7% · higher than 6% of 408
  • Revenue growth209.1% · higher than 90% of 438
  • Price / sales35.3× · lower than 22% of 339
  • Price / book19.1× · lower than 8% of 534
  • FCF yield-9.6% · higher than 58% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Verastem, Inc.🇺🇸$1.1 B—-677.7%+209.1%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 19, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikimedia Commons, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Verastem, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Verastem, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Verastem, Inc.? Suggest a correction